Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT05413655
PHASE2

A Study of Oral EX039 in Subjects with Mild Alzheimer's Disease

Sponsor: Excelsior

View on ClinicalTrials.gov

Summary

This is a phase 2, randomized, double-blind, placebo-controlled study of oral EX039 as add-on to Acetylcholine Esterase Inhibitors in subjects with mild Alzheimer's disease.

Official title: A Phase 2, Randomized, Double Blind, Placebo-Controlled Study of Oral EX039 As Add-on to Acetylcholine Esterase Inhibitors in Subjects with Mild Alzheimer's Disease

Key Details

Gender

All

Age Range

50 Years - 80 Years

Study Type

INTERVENTIONAL

Enrollment

120

Start Date

2022-08-08

Completion Date

2027-02

Last Updated

2025-02-26

Healthy Volunteers

No

Interventions

DRUG

EX039

The dosage form of EX039 is the capsule for oral use

DRUG

Placebo

The dosage form of Placebo is the capsule for oral use

Locations (1)

National Taiwan University Hospital

Taipei, Taiwan